Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Ladoire

Showing results (101-110 of 167) with videos related to

Pageof 17
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 18, 2016
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With ChemotherapyJorge D Ramos, Martin F Casey, Aristotelis Bamias, et al.
European Urology Oncology|May 11, 2024
Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical TrialLoic Ah-Thiane, Loic Campion, Nedjla Allouache, et al.
Breast Cancer Research and Treatment|November 23, 2022
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registrySamia Kada Mohammed, Tienhan Sandrine Dabakuyo Yonli, Isabelle Desmoulins, et al.
Breast (Edinburgh, Scotland)|September 7, 2024
Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registrySylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, et al.
NPJ Breast Cancer|March 5, 2022
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencingLoïck Galland, Elise Ballot, Hugo Mananet, et al.
Clinical Genitourinary Cancer|August 27, 2023
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVORENGuillemette Guilhem-Ducléon, Cécile Dalban, Sylvie Negrier, et al.
Autophagy|March 17, 2016
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancerSylvain Ladoire, David Enot, Laura Senovilla, et al.
Breast Cancer Research : BCR|February 7, 2025
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruptionMorgane Lopez, Laurie Spehner, Fabrice André, et al.
Cancer Research|April 27, 2013
SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growthHélène Berger, Frédérique Végran, Madijd Chikh, et al.
The Journal of Clinical Investigation|July 1, 2025
Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doubletLaura Kalfeist, Fanny Ledys, Stacy Petit, et al.
Pageof 17

Showing results (101-110 of 167) with videos related to

Sort By:
Pageof 17
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 18, 2016
The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With ChemotherapyJorge D Ramos, Martin F Casey, Aristotelis Bamias, et al.
European Urology Oncology|May 11, 2024
Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical TrialLoic Ah-Thiane, Loic Campion, Nedjla Allouache, et al.
Breast Cancer Research and Treatment|November 23, 2022
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registrySamia Kada Mohammed, Tienhan Sandrine Dabakuyo Yonli, Isabelle Desmoulins, et al.
Breast (Edinburgh, Scotland)|September 7, 2024
Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registrySylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, et al.
NPJ Breast Cancer|March 5, 2022
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencingLoïck Galland, Elise Ballot, Hugo Mananet, et al.
Clinical Genitourinary Cancer|August 27, 2023
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVORENGuillemette Guilhem-Ducléon, Cécile Dalban, Sylvie Negrier, et al.
Autophagy|March 17, 2016
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancerSylvain Ladoire, David Enot, Laura Senovilla, et al.
Breast Cancer Research : BCR|February 7, 2025
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruptionMorgane Lopez, Laurie Spehner, Fabrice André, et al.
Cancer Research|April 27, 2013
SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growthHélène Berger, Frédérique Végran, Madijd Chikh, et al.
The Journal of Clinical Investigation|July 1, 2025
Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doubletLaura Kalfeist, Fanny Ledys, Stacy Petit, et al.
Pageof 17